ClinicalTrials.gg

Program

RS-113

A development code. Also written as “RS-113, 160 mg”, “RS-113, 240 mg” and “RS-113, 320 mg”.

Its studies are mostly in Prostatic Neoplasms, led by R-Pharm.

Furthest: phase 2, since Apr 21, 20261 company-led study, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
R-Pharm11 open or runningphase 2since Apr 21, 2026Apr 21, 2026none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 21, 2026First study: phase 2 study in Metastatic Castration-resistant Prostate CancerFirst studyNCT07553988 · 120 enrolled · Russia

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07553988Metastatic Castration-resistant Prostate Cancer · Russia2Active, not recruitingMay 14, 2026120

How it is read

Names in the registry

  • “RS-113, 160 mg”, 1 entry
  • “RS-113, 240 mg”, 1 entry
  • “RS-113, 320 mg”, 1 entry

Codes read as this program: RS113.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.